Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study - Concepedia

Concepedia

Publication | Open Access

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

DOI Full Paper Access

120

Citations

24

References

2009

Year

Stephen Leong, Roger B. Cohen, Daniel L. Gustafson, Corey J. Langer, D. Ross Camidge, Kristin Padavic, Lia Gore, Margaret Smith, Laura Q.M. Chow, Margaret von Mehren,

Journal of Clinical Oncology

Abstract

Mapatumumab is well-tolerated up to 20 mg/kg in combination with paclitaxel and carboplatin. There are no apparent pharmacokinetic interactions among the drugs. Preliminary anticancer activity demonstrated clinical benefit for the majority of these patients.

References

	Year	Citations

Page 1